OncologyTube Professional - Patients Click Here
19,874 video views
Loading........
Description: Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the Agreement of a Single IRB Review | Single IRG Approval Applies to Other Five Centers
01:47
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the Agreement of a Single IRB Review | Single IRG Approval Applies to Other Five Centers
by:Cancer-News | 22 views
02:06
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, shares how the Study Brought Together Six Academic Centers | BMS, Apexigen, Inc., Cancer Research Institute, etc.
by:Cancer-News | 40 views
01:30
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains how No One Else is Focusing on Pancreatic Cancer | Answer What Makes Biology of Pancreatic Cancer Unique
by:Cancer-News | 42 views
00:50
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Focuses on Frontline Metastatic Pancreatic Cancer | Patients Get Added Benefits of Investigational Agents.
by:Cancer-News | 16 views
01:02
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Follows Patients for a Period of Time in the Beginning | Once Safety Profile is Cleared, Open Enrollment Occurs
by:Cancer-News | 23 views
03:04
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, talks about Lead Investigator of Study, Dr. Vonderheide | Develop New Agents to help Pancreatic Cancer Patients
by:Cancer-News | 15 views
00:51
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the combination of Gemcitabine + Abraxane - Standard for Pancreatic Cancer | Investigational Agents - Nivolumab-Anti-​PD1 & Anti-CD40.
by:Cancer-News | 22 views
01:58
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, talks about the Trial Combining Immunotherapy & Chemotherapy | Survival will be the Primary Endpoint of the Study.
by:Cancer-News | 11 views
02:19
Dr. John Kisiel, MD, Mayo Clinic, talks Setting Specificity and Sensitivity for Tests | Involves recruiting up to 500 At-Risk Control Patients for DDW 2018
by:Cancer-News | 31 views
01:04
Dr. John Kisiel, MD, Mayo Clinic, talks Sensitivity for BCLC for Stage A was 93%| Detect Hepatocellular Carcinoma Lesions in Future for DDW 2018.
by:Cancer-News | 23 views

About Cancer-News


Links
Channel Url: